Skip to main content
xMedica

NCT07817251ClinicalTrials.gov

Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema

Safety And Tolerability of 3 Switch Regimens From Semaglutide 1.0 mg and 2.0 mg to Co-Administered Cagrilintide and Semaglutide (Cagrisema) in Participants With Type 2 Diabetes

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in…

Phase 3210 participants sought40 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-09-14; recorded start 2026-09-16
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 351 other studies in this databaseCounted from the lead sponsor named in the record (Novo Nordisk A/S)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 40 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 210 participants (target), run at 40 sites.

How this score is built
  • Enrolment22/40

    210 participants (target)

  • Site count19/25

    40 sites

  • Country count0/15

    Single country

  • Planned duration4/10

    Planned over about 10 months

  • Sponsor scale9/10

    Novo Nordisk A/S has led 339 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose of this clinical study is to look at the safety and tolerability of switching from semaglutide to CagriSema, for participants who have type 2 diabetes. All participants will get CagriSema, the treatment being tested. Participants will be in this clinical study for about 6 months.

Conditions

  • Diabetes Mellitus, Type 2

Eligibility

Eligibility
SexAll
Ages18 Years – No maximum
Healthy volunteersNo

Eligibility as written in the registry

Inclusion criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Diagnosed with type 2 diabetes mellitus (T2DM) greater than or equal to (≥) 180 days before screening. * Stable once-weekly dose ≥ 90 days before screening of branded s.c. semaglutide. Branded semaglutide s.c. includes Ozempic and Wegovy. Participants on compounded semaglutide are ineligible. * Not on treatment with oral antidiabetic drugs or on stable daily dose(s) ≥ 90 days before screening of any of the following antidiabetic drug(s) or combination regimen at effective or maximum tolerated dose (MTD) as judged by the investigator: metformin and/or sodiumglucose co-transporter-2 (SGLT2) inhibitor. * Glycated haemoglobin (HbA1c) 6.5-10.5 percentage (%) (48-91 millimoles per mole \[mmol/mol\]) (both inclusive) as determined by central laboratory at screening. * Body mass index (BMI) ≥ 25 kilograms per square meter (kg/m\^2) at screening. BMI will be calculated in the electronic case report form (eCRF) based on height and body weight at screening. Exclusion criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method from screening. * Renal impairment with estimated glomerular filtration rate (eGFR) less than (\<) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) as determined by central laboratory at screening. * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * A self-reported change in body weight \> 5% within 90 days before screening irrespective of medical records. * Use of personal continuous glucose monitoring (CGM) devices. Participants currently using personal CGM devices must discontinue use prior to screening and throughout study participation.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 3
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment210 participants sought

Sponsor and collaborators

  • Novo Nordisk A/S Sponsor

Arms and interventions

  • CagriSema dose 1EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide subcutaneously (s.c.) will switch to once-weekly CagriSema dose 1.

  • CagriSema dose 2EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 2, followed by dose 1.

  • CagriSema dose 3EXPERIMENTAL

    Participants previously treated with once-weekly semaglutide s.c. will switch to once-weekly CagriSema dose 3, followed by dose 2 and dose 1.

Interventions

  • Drug CagriSema

    CagriSema will be administered s.c. once weekly.

Outcome measures

  1. Primary outcome

    Number of treatment emergent adverse events (TEAEs)

    Measured as count of events.

    Time frame From baseline (Week 0) to end of treatment (Week 16)

  2. Secondary outcome

    Number of TEAEs

    Measured as count of events.

    Time frame From baseline (Week 0) to end of study (Week 22)

  3. Secondary outcome

    Number of TEAEs

    Measured as count of events.

    Time frame From baseline (Week 0) to Week 8

  4. Secondary outcome

    Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimoles per liter [mmol/L] (54 milligrams per deciliter [mg/dL]), confirmed by blood glucose [BG] meter)

    Measured as count of episodes.

    Time frame From baseline (Week 0) to end of study (Week 22)

  5. Secondary outcome

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Time frame From baseline (Week 0) to end of study (Week 22)

  6. Secondary outcome

    Number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L (54 mg/dL), confirmed by BG meter)

    Measured as count of episodes.

    Time frame From baseline (Week 0) to Week 8

  7. Secondary outcome

    Number of severe hypoglycaemic episodes (level 3): hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery, with no specific glucose threshold

    Measured as count of episodes.

    Time frame From baseline (Week 0) to Week 8

  8. Secondary outcome

    Number of participants who discontinued due to gastrointestinal (GI) adverse events (AEs)

    Measured as count of participants.

    Time frame From baseline (Week 0) to end of treatment (Week 16)

Dates

Dates
Start dateSeptember 16, 2026 (actual)
Primary completionJune 9, 2027 (estimated)
CompletionJuly 21, 2027 (estimated)
First postedSeptember 14, 2026 (actual)
Last updatedSeptember 30, 2026
Results postedNot stated in the registry record
Status last verifiedSeptember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

37 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Albuquerque Clinical Trials Inc.AlbuquerqueNew MexicoRecruiting
Amarillo Med Spec LLPAmarilloTexasRecruiting
Texas Diabetes & EndocrinologyAustinTexasRecruiting
Northern Pines Hlth Ctr, PCBuckleyMichiganRecruiting
North Texas Endocrine CenterDallasTexasRecruiting
Northeast Research InstituteFleming IslandFloridaRecruiting
Diabetes and Thyroid Center of Fort WorthFort WorthTexasRecruiting
Ark Clinical ResearchFountain ValleyCaliforniaRecruiting
Gilbert Center For Family MedicineGilbertArizonaRecruiting
Thrive Clinical Research GroupGlendoraCaliforniaRecruiting
PharmQuest Life Sciences LLCGreensboroNorth CarolinaRecruiting
AGA Clinical TrialHialeahFloridaRecruiting
East West Med Res InstHonoluluHawaiiRecruiting
JCCT- Juno NW HoustonHoustonTexasRecruiting
Sante Clinical ResearchKerrvilleTexasRecruiting
Scripps Whittier Diabetes InstLa JollaCaliforniaRecruiting
Palm Research Center Inc-VegasLas VegasNevadaRecruiting
DCOL Ctr for Clin ResLongviewTexasRecruiting
Downtown LA Res Ctr. Inc.Los AngelesCaliforniaRecruiting
Advanced Medical ResearchMaumeeOhioNot yet recruiting
Adult Medicine of Lake County, IncMt. DoraFloridaRecruiting
Clinical Research AssociatesNashvilleTennesseeRecruiting
Tidewater Physicians Multispecialty GroupNewport NewsVirginiaRecruiting
Alliance for Multispecialty ResearchNewtonKansasRecruiting
North Hills Medical Research IncNorth Richland HillsTexasRecruiting
Valley Clinical Trials, Inc.NorthridgeCaliforniaRecruiting
Optimal Research SitesOrange CityFloridaRecruiting
Dream Team Clinical ResearchPomonaCaliforniaRecruiting
Clinical Trials Research_SacramentoSacramentoCaliforniaRecruiting
J.Lewis Research IncSalt Lake CityUtahRecruiting
NE Clin Res of San AntonioSan AntonioTexasNot yet recruiting
Linda Vista Health Care CtrSan DiegoCaliforniaRecruiting
Diabetes & Endo Treatment SpecSandy CityUtahNot yet recruiting
Endeavor HealthSkokieIllinoisRecruiting
Chrysalis Clinical ResearchSt. GeorgeUtahRecruiting
Cotton O'Neil Diabetes & EndocrinologyTopekaKansasRecruiting
Chase Medical Research LLCWaterburyConnecticutRecruiting
Iowa Diabetes & Endo Res CtrWest Des MoinesIowaRecruiting
Metabolic Research Institute IncWest Palm BeachFloridaRecruiting
Accellacare WilmingtonWilmingtonNorth CarolinaRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. September 30, 2026

    Status changed

    Status changed from Not yet recruiting to Recruiting

    NOT_YET_RECRUITINGRECRUITING

  2. September 30, 2026

    Recruitment opened

    Recruitment opened

    NOT_YET_RECRUITINGRECRUITING